SynOx Therapeutics Ltd

Syndax

This biopharmaceutical company develops and commercialises targeted therapies for adult and paediatric patients with cancer and chronic graft-versus-host disease.

Spica Therapeutics

This biotechnology firm develops monoclonal antibody therapies that target pathogenic macrophage subsets to treat patients with cancer and fibroinflammatory diseases.

Macomics

The company develops macrophage-modulating antibody therapies and precision medicines for patients with cancer and fibrotic diseases.

Signadori Bio

This biopharmaceutical company develops a monocyte-based cell therapy platform to treat patients with solid tumours.

Siamab

This biopharmaceutical firm develops glycan-targeted monoclonal antibodies and therapeutics for patients with solid tumours including ovarian, pancreatic, and prostate cancers.

Sidewinder Therapeutics

The biopharmaceutical company develops bispecific antibody-drug conjugates to provide precision medicines for patients with difficult-to-treat cancer and rare diseases.

Arxx Therapeutics

This biotechnology firm develops monoclonal antibody therapies for patients suffering from chronic inflammatory and fibrotic diseases.

Tacalyx

This company develops antibody-based therapeutics targeting tumour associated carbohydrate antigens for the treatment of solid tumours in cancer patients.